Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enpatoran in Active Cutaneous Manifestations of Lupus Erythematosus (ELOWEN-1)
NCT07470957Phase 3Not yet recruiting
- Sponsor
- EMD Serono
- Start
- Mar 2026
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of enpatoran in cutaneous lupus erythematosus (CLE), sponsored by EMD Serono. Primary endpoint: Cutaneous Lupus Erythematosus Disease Area and Severity Index 70 Response at 24 weeks. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
enpatoran
03
Conditions
cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT07470957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07470957.